AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Regorafenib'
:
Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Publication Year: 2010
DOI: https://doi.org/10.1002/ijc.25864
Abstract:
Add to Library
Authors:
Scott M. Wilhelm
Jacques Dumas
Lila Adnane
Mark Lynch
Christopher A. Carter
Gunnar Schütz
Karl‐Heinz Thierauch
Dieter Zopf
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Publication Year: 2016
DOI: https://doi.org/10.1016/s0140-6736(16)32453-9
Abstract:
Add to Library
Authors:
Jordi Bruix
Shukui Qin
Philippe Merle
Alessandro Granito
Yi‐Hsiang Huang
G. Bodoky
Marc Pracht
Osamu Yokosuka
Olivier Rosmorduc
В. В. Бредер
René Gérolami
Gianluca Masi
Paul J. Ross
Tianqiang Song
Jean-Pierre Bronowicki
Isabelle Ollivier‐Hourmand
Masatoshi Kudo
Ann‐Lii Cheng
Josep M. Llovet
Richard S. Finn
Marie-Aude LeBerre
Annette Baumhauer
Gerold Meinhardt
Guohong Han
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Publication Year: 2012
DOI: https://doi.org/10.1016/s0140-6736(12)61900-x
Abstract:
Add to Library
Authors:
Axel Grothey
Eric Van Cutsem
Alberto Sobrero
Salvatore Siena
Alfredo Falcone
Marc Ychou
Yves Humblet
Olivier Bouché
Laurent Mineur
Carlo Barone
Antoine Adenis
Josep Tabernero
Takayuki Yoshino
Heinz‐Josef Lenz
Richard M. Goldberg
Daniel J. Sargent
Frank Cihon
Lisa Cupit
Thierry André
Dirk Laurent
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Publication Year: 2012
DOI: https://doi.org/10.1016/s0140-6736(12)61857-1
Abstract:
Add to Library
Authors:
George D. Demetri
Peter Reichardt
Yoon‐Koo Kang
Jean‐Yves Blay
Piotr Rutkowski
Hans Gelderblom
Peter Hohenberger
Michael Leahy
Margaret von Mehren
Heikki Joensuu
Giuseppe Badalamenti
Martin E. Blackstein
Axel Le Cesne
Patrick Schöffski
Robert G. Maki
Sebastian Bauer
Binh Bui Nguyen
Jianming Xu
Toshirou Nishida
John Chung
Christian Kappeler
Iris Kuss
Dirk Laurent
Paolo G. Casali
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
Publication Year: 2020
DOI: https://doi.org/10.1200/jco.19.03296
Abstract:
Add to Library
Authors:
Shota Fukuoka
Hiroki Hara
Naoki Takahashi
Takashi Kojima
Akihito Kawazoe
Masako Asayama
Takako Yoshii
Daisuke Kotani
Hitomi Tamura
Yuichi Mikamoto
Nami Hirano
Masashi Wakabayashi
Shogo Nomura
Akihiro Sato
Takeshi Kuwata
Yosuke Togashi
Hiroyoshi Nishikawa
Kohei Shitara
Regorafenib for cancer
Publication Year: 2012
DOI: https://doi.org/10.1517/13543784.2012.684752
Abstract:
Add to Library
Authors:
Dirk Strumberg
Beate Schultheis
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
Publication Year: 2012
DOI: https://doi.org/10.1038/bjc.2012.153
Abstract:
Add to Library
Authors:
Dirk Strumberg
M. E. Scheulen
Beate Schultheis
Heike Richly
Annette Frost
Martin Büchert
O. Christensen
Michael Jeffers
Roland Heinig
Oliver Boix
K. Mross
Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
Publication Year: 2013
DOI: https://doi.org/10.1158/1535-7163.mct-12-1162
Abstract:
Add to Library
Authors:
Lotfi Abou‐Elkacem
Susanne Arns
Gunnar Brix
Felix Gremse
Dieter Zopf
Fabian Kießling
Wiltrud Lederle
A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Publication Year: 2012
DOI: https://doi.org/10.1158/1078-0432.ccr-11-1900
Abstract:
Add to Library
Authors:
K. Mross
Annette Frost
Simone Steinbild
Susanne Hedbom
Martin Büchert
Ulrike Fasol
Clemens Unger
Jörn Krätzschmar
Roland Heinig
Oliver Boix
Olaf Christensen
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
Publication Year: 2012
DOI: https://doi.org/10.1200/jco.2011.39.9394
Abstract:
Add to Library
Authors:
Suzanne George
Qian Wang
Michael C. Heinrich
Christopher L. Corless
Mei‐Jun Zhu
James E. Butrynski
Jeffrey A. Morgan
Andrew J. Wagner
Edwin Choy
William D. Tap
Jeffrey T. Yap
Annick D. Van den Abbeele
Judith Manola
Sarah Solomon
Jonathan A. Fletcher
Margaret von Mehren
George D. Demetri
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Publication Year: 2019
DOI: https://doi.org/10.1053/j.gastro.2019.01.261
Abstract:
Add to Library
Authors:
Michael Teufel
Henrik Seidel
Karl Köchert
Gerold Meinhardt
Richard S. Finn
Josep M. Llovet
Jordi Bruix
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Publication Year: 2019
DOI: https://doi.org/10.1200/jco.18.02374
Abstract:
Add to Library
Authors:
Lara E. Davis
Vanessa Bolejack
Christopher W. Ryan
Kristen N. Ganjoo
Elizabeth T. Loggers
Sant P. Chawla
Mark Agulnik
Michael B. Livingston
Damon R. Reed
Vicky L. Keedy
Daniel A. Rushing
Scott H. Okuno
Denise K. Reinke
Richard F. Riedel
Steven Attia
Leo Mascarenhas
Robert G. Maki
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial
Publication Year: 2016
DOI: https://doi.org/10.1200/jco.2015.65.1901
Abstract:
Add to Library
Authors:
Nick Pavlakis
Katrin Marie Sjoquist
Andrew Martin
Eric Tsobanis
Sonia Yip
Yoon‐Koo Kang
Yung‐Jue Bang
Thierry Alcindor
Christopher J. O’Callaghan
Margot J. Burnell
Niall C. Tebbutt
Sun Young Rha
Jeeyun Lee
Y. Choi
Lara Lipton
Mark Wong
Andrew Strickland
Jin Won Kim
John Zalcberg
John Simes
David Goldstein
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
Publication Year: 2013
DOI: https://doi.org/10.1016/j.ejca.2013.05.028
Abstract:
Add to Library
Authors:
Jordi Bruix
Won Young Tak
Antonio Gasbarrini
Armando Santoro
M. Colombo
Ho-Yeong Lim
Vincenzo Mazzaferro
Reiner Wiest
María Reig
Thierry André
Luigi Bolondi
Regorafenib
Publication Year: 2018
DOI: https://doi.org/10.1007/978-3-319-91442-8_3
Abstract:
Add to Library
Authors:
Thomas Jens Ettrich
Thomas Seufferlein
Found 13635 results in 0.122 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"